Connect with us

International News

Illumina offers new genotyping array and scientific contribution to genome centers

Illumina, Inc. has launched its new high-density genotyping array, the Infinium Global Diversity Array that was developed for and inspired by the All of Us research program, a historic effort to gather data from one million or more people living in the United States, to accelerate human disease research and improve health. The All of Us research program aims to build a nationwide community in the United States of at least one million participants from all walks of life, including groups that have been historically underrepresented in research. In September, the All of Us research program awarded funds totaling USD 28.6 million to three genome centers around the country.

These centers will generate genomic data from biosamples contributed by the program’s participants. Ultimately, this information will become a critical component in the program’s precision medicine research platform, a national resource to support studies on a variety of important health questions. The All of Us research program is funded and led by the National Institutes of Health (NIH), part of the US Department of Health and Human Services.

Recognizing the significant impact that this project will have on the future of healthcare, Illumina is making a scientific contribution to the program by providing the new Infinium Global Diversity Array to process up to one million samples to the three genome centers, at no charge. The new array will be a high-density chip that has been designed to enable achievement of the primary genotyping-based goals of the project. Those goals are unparalleled coverage of a highly diverse cohort and the ability to return results to participants such as those indicated by the ACMG-59 Gene List and key pharmacogenomic variants.

Some of these genes are associated with potentially life-threatening health conditions, ranging from familial hypercholesterolemia, to breast and ovarian cancer. The array will become commercially available for others to use in mid-2019. In addition to the new genotyping array, the awarded genome centers will employ Illumina’s NovaSeq 6000 Sequencing Platform to conduct the whole genome sequencing for the All of Us research program.

Copyright © 2024 Medical Buyer

error: Content is protected !!